Navigation Links
Roche Diagnostics Supports Fight Against MRSA as a Sponsor of Annual World MRSA Day
Date:9/28/2010

INDIANAPOLIS, Sept. 28 /PRNewswire/ -- As part of its ongoing work in the prevention and control of serious infections in healthcare settings, Roche Diagnostics is pleased to announce its sponsorship of the 2nd Annual World MRSA Day, which will commence with a kick-off event at Loyola University in Chicago on October 1, 2010. Organized by the MRSA Survivors Network, the goal of World MRSA Day is to highlight the importance of a comprehensive approach to controlling MRSA (methicillin-resistant Staphylococcus aureus), a type of bacterium that is resistant to common antibiotics and can cause serious infections. High rates of infection and mortality and high costs of treatment due to healthcare-associated infections (HAIs) caused by MRSA are a critical issue for healthcare facilities worldwide.

"The goal for this event is to raise widespread awareness of the need for greater MRSA prevention, screening, treatment and education," said Jeanine Thomas, MRSA survivor and founder of the MRSA Survivors Network, the organization that started the event. "We also hope to encourage world health organizations and government officials to provide greater resources and leadership toward focusing on the response to the MRSA epidemic and preventing its spread. Through prevention, we can save lives."

The kick-off event will begin with a closed press conference at 10:00 a.m. and then will be opened to the public at 10:30 for a remembrance ceremony.  The main event will follow and include an awards ceremony to recognize those individuals and organizations that have made a significant contribution to raising awareness and education about MRSA. The keynote speaker will be world-renowned MRSA expert and former Centers for Disease Control and Prevention (CDC) scientist, William R. Jarvis, M.D.  Dr. Jarvis will also be presented with the "Barry M. Farr Lifetime Achievement Award" during the ceremony.  

"While MRSA is preventable, approximately two million HAIs and 90,000 deaths are attributed to it each year in the United States, which underscores the critical need for greater awareness of the issue and the potential solutions," said Jack Phillips, president and CEO of Roche Diagnostics Corporation. "Roche applauds the MRSA Survivors Network for bringing this important issue to the forefront and we are honored to be a sponsor of World MRSA Day. We believe that more education, together with effective screening and infection control programs, can significantly reduce the spread of MRSA and its consequences."

Other participants in the kick-off event include local government officials, infection control experts and healthcare professionals, MRSA survivors, and those who have lost loved ones to MRSA.

"The good news is that there are some relatively simple steps that can be taken to control the spread of MRSA, such as appropriate screening and testing, hand washing and careful use of antibiotics," said Lance Peterson, M.D., FASCP, epidemiologist and a founder of the MRSA screening program at NorthShore University HealthSystem in Evanston, Illinois. "This event is important because it will help to raise awareness of these steps and the importance of following them among both healthcare professionals and the general public."

About HAIs and MRSA screeningHealthcare-associated infections caused by MRSA are a tremendous burden for healthcare systems and hospitals and are associated with significant healthcare costs. In addition, community-associated MRSA (CA-MRSA) infection has spread in the U.S., underscoring the need for comprehensive infection control programs along with more rapid and reliable MRSA screening methods. In response to this public health issue, an increasing number of states have passed legislation requiring mandatory reporting and/or screening for HAIs.  

In July 2010, the United States Food & Drug Administration (FDA) cleared Roche's LightCycler® MRSA Advanced Test, a qualitative in-vitro diagnostic test for the direct detection of nasal colonization with methicillin-resistant Staphylococcus aureus (MRSA) to aid in the prevention and control of MRSA infections in healthcare settings. The test is performed on the LightCycler® 2.0 Instrument with nasal swab specimens from patients suspected of colonization.

About RocheHeadquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche's personalized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2009, Roche had over 80,000 employees worldwide and invested almost 10 billion Swiss francs in R&D. The Group posted sales of 49.1 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com or www.roche-diagnostics.us.

All trademarks used or mentioned in this release are protected by law.

For further information, please contact: Betsy Cox Director, Corporate Communications

Roche Diagnostics Corporation

Indianapolis, IN(317) 521-3911betsy.cox@roche.com
'/>"/>

SOURCE Roche Diagnostics Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Roche Receives FDA Approval for Second-Generation Hepatitis B Viral Load Test
2. AstraZeneca Joins Rochester Initiative to Further Cardiac Safety
3. Roche Launches New Initiative - Roche Goes to Town
4. Roche Diagnostics Introduces Full Line of 9-Minute STAT Assays for Cardiac Biomarker Testing on cobas 6000 Analyzer Series
5. Roche Receives FDA Clearance for U.S. Launch of cobas 8000 Modular Analyzer Series for High-Volume Laboratory Testing
6. New England Biolabs Launches NEBNext™ Quick DNA Sample Prep Reagent Sets for Use With Roche/454 Next Generation Sequencing Platforms
7. caprotec bioanalytics Announces the Successful Completion of a Collaborative Research Project With Roche
8. Rochester Medical Corporation Honored by Premier Healthcare Alliance for Exceptional Supplier Performance
9. Roche Holds Seventh Annual Childrens Walk
10. Roche Symposium Showcases Accomplishments of Next Generation of Chemists
11. ThromboGenics and BioInvent to Receive EUR10 Million Milestone as Partner Roche Begins New Clinical Study with TB-403
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... SAN FRANCISCO, Calif. , June 24, 2016 ... GBT ), a biopharmaceutical company developing novel therapeutics ... significant unmet needs, today announced the closing of ... shares of common stock, at the public offering ... shares in the offering were offered by GBT. ...
(Date:6/24/2016)... Dublin - ... " Global Markets for Spectroscopy Equipment" report ... This report focuses on the global market of ... applications in various applications. The report deals with spectroscopy ... industries: pharmaceutical and biotechnology, food and beverage, and environmental ...
(Date:6/24/2016)... 24, 2016 The Academy of Managed Care ... that would allow biopharmaceutical companies to more easily ... make formulary and coverage decisions, a move that addresses ... medicines. The recommendations address restrictions in the ... the drug label, a prohibition that hinders decision makers ...
Breaking Medicine Technology:
(Date:6/26/2016)... , ... June 26, 2016 , ... On June 10-11, ... of the 2016 Cereal Festival and World’s Longest Breakfast Table in Battle Creek, MI, ... the city’s history as home to some of the world’s leading providers of cereal ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... ... health policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, ... work on several important health care topics including advance care planning, healthcare costs ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe ... from the David Geffen School of Medicine at UCLA. He trained in Internal Medicine ... his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the ...
(Date:6/24/2016)... ... 24, 2016 , ... Those who have experienced traumatic events may suffer from ... avenues, such as drug or alcohol abuse, as a coping mechanism. To avoid this ... coping following a traumatic event. , Trauma sufferers tend to feel a range of ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, an ... Dr. Cheng has extensive experience with all areas of orthodontics, including robotic Suresmile ... orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can ...
Breaking Medicine News(10 mins):